Hercules Capital, Inc. logo HTGC - Hercules Capital, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 19
HOLD 11
SELL 1
STRONG
SELL
0
| PRICE TARGET: $15.50 DETAILS
HIGH: $15.50
LOW: $15.50
MEDIAN: $15.50
CONSENSUS: $15.50
DOWNSIDE: 3.55%

Stock News

Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029

Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029

SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has closed an upsized underwritten public offering of $400.0 million in aggregate principal amount of 6.700% notes due October 2029 (the “Notes”). The Notes are unsecured and bear interest at a rate of 6.700% per year, payable semiannually, will mature on October 8, 2029 and may be redeemed in whole or in part at any time or from time to time at the.

Oct 08, 2026 12:05 PM • businesswire.com
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility strengthens Rocket's financial position and provides access to additional capital to support executi.

Oct 06, 2026 12:12 PM • businesswire.com
Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029

Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029

SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has priced an underwritten public offering of $400.0 million in aggregate principal amount of 6.70% notes due October 2029 (the “Notes”). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on October 8, 2026.The Notes are unsecured and bear interest at a rate of 6.70% per.

Oct 05, 2026 12:05 PM • businesswire.com
NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies

NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Technologies, LLC (NorthStar), the first commercial-scale producer of no-carrier-added actinium-225 (n.c.a. Ac-225) using electron-accelerator technology, today announced a multi-year growth capital facility of up to $185 million with Hercules Capital, Inc. (NYSE: HTGC) to support NorthStar's continued growth and expansion. The financing, including $100 million upfront, will accelerate investment in isotope production and in clinical and commerci.

Sep 29, 2026 03:00 AM • businesswire.com

Price Targets